Aneurysmal Subarachnoid Hemorrhage Clinical Trial
Official title:
Efficacy Study of Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage
This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.
Astragalus membranaceus (AM, Huang-Chi) is a Chinese herb used extensively in China as a
traditional treatment to treat stroke for a long time, and a number of studies have shown
that AM can reduce cerebral infarction area and has anti-oxidation activity. Our previous
studies have demonstrated enhanced recovery of neurologic function in patients with acute
hemorrhagic stroke who received AM. It is hypothesized that AM either reduces inflammatory
response or reduces perihematomal edema.
Subarachnoid hemorrhage secondary to rupture of a cerebral aneurysm is a medical condition
associated with a high morbidity and mortality; approximately 10-15% of patients die before
reaching medical care, and overall mortality is approximately 45%. Of those that survive, 30%
suffer permanent disability graded as moderate to severe, and two-thirds of survivors never
return to the same quality of life as they had prior to their hemorrhage. A large number of
patients (30-70%) who are able to make it to the hospital and have successful treatment of
their aneurysm will develop delayed cerebral vasospasm that is related to the blood clot from
their initial aneurysm rupture. Of patients that survive their initial aneurysm rupture,
vasospasm results in an additional 7% mortality and another 7% of severe disabilities
secondary to ischemic strokes from severe spasm of cerebral arteries.
This research is trying to see if AM can enhance the clinical prognosis for spontaneous
aneurysm ruptured subarachnoid hemorrhage patients. All procedures done as a part of this
study are standard hospital care procedures done to treat aneurysmal subarachnoid hemorrhage
according to the AHA/ASA guideline.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03209830 -
Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
| Completed |
NCT05131295 -
Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.
|
Phase 3 | |
| Recruiting |
NCT04583163 -
Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
|
||
| Not yet recruiting |
NCT05483751 -
Micro- and Macrovascular Parameters in Delayed Cerebral Ischemia
|
||
| Recruiting |
NCT01098890 -
Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
| Completed |
NCT00692744 -
Quality of Life in Elderly After Aneurysmal Subarachnoid Hemorrhage (SAH)
|
N/A | |
| Recruiting |
NCT05738083 -
Machine Learning-based Prediction of Complications, Disability, and Death in Patients With aSAH
|
||
| Completed |
NCT03754335 -
SubArachnoid Hemorrhage HEadache Treated by Lumbar Puncture
|
N/A | |
| Completed |
NCT06076590 -
Impact of Multiple Electrolytes Injection Ⅱ and Saline on Hyperchloremia in Patients With Aneurysmal Subarachnoid Hemorrhage:a Pilot Study
|
Phase 4 | |
| Recruiting |
NCT04148105 -
Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)
|
Phase 4 | |
| Recruiting |
NCT04548401 -
Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage
|
||
| Recruiting |
NCT02129413 -
Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm
|
N/A | |
| Terminated |
NCT00487461 -
Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
| Recruiting |
NCT05974111 -
COAgulation Disorders in Ischaemic and Haemorrhagic Stroke
|
||
| Not yet recruiting |
NCT06288659 -
aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial
|
N/A | |
| Recruiting |
NCT03706768 -
Degradation of the Glycocalyx in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
| Recruiting |
NCT06284642 -
Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK)
|
Phase 4 | |
| Recruiting |
NCT01773200 -
Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
| Completed |
NCT02026596 -
SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage
|
N/A | |
| Recruiting |
NCT04566991 -
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
|
Phase 2 |